Seizure potential of concomitant medications and radiographic contrast media agents

Annals of Pharmacotherapy

Volumn 37, Issue 10, 2003, Pages 1506-1510

  Fedutes, Bethany A ^a,b   Ansani, Nicole T ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Contraindications; Contrast media; Iohexol; Metrizamide; Myelogram; Myelography; Seizure

Indexed keywords

CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CONTRAST MEDIUM; IODINATED CONTRAST MEDIUM; IOHEXOL; LEVOMEPROMAZINE; METRIZAMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NONIONIC CONTRAST MEDIUM; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ABSENCE; ADULT; AGED; COMPLEX PARTIAL SEIZURE; DRUG WITHDRAWAL; EEG ABNORMALITY; EPILEPTIC STATE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INCIDENCE; MALE; MENINX DISORDER; MENTAL DISEASE; MYELOGRAPHY; NAUSEA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEIZURE; SEIZURE THRESHOLD; SLEEP DISORDER; VERTIGO;

CONTRAST MEDIA; DRUG INTERACTIONS; DRUG LABELING; DRUG THERAPY; HUMANS; META-ANALYSIS; SEIZURES;

EID: 0141557872     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C464     Document Type: Review

References (17)

1. Product information. Omnipaque (iohexol). Princeton, NJ: Nycomed. March 2000.
2. Junck L, Marshal WH. Neurotoxicity of radiological contrast agents. Ann Neurol 1983;13:469-84.
3. Hanus PM. Metrizamide: a review with emphasis on drug interactions. Am J Hosp Pharm 1980;37:510-3.
4. Shaw DD, Bach-Gansmo T, Dahlstrom K. Iohexol: summary of North America and European clinical trials in adult lumbar, thoracic, and cervical myelography with a new nonionic contrast medium. Invest Radiol 1985;20(1 suppl):S44-50.
5. Hindmarsh T, Grepe A, Widen L. Metrizamide-phenothiazine interaction. Acta Radiol Diagn 1975;16:129-34.
6. Wray AR, Templeton J, Laird JD. Seizure following lumbar myelography with metrizamide (letter). BMJ 1978;1:1787.
7. Russel D, Anke IM, Nyberg-Hansen R, Slettnes O, Sortland O, Veger T. Complex partial status epilepticus following myelography with metrizamide. Ann Neurol 1980;8:325-7.
8. Amer-Ferrer G, Alonso-Marne T, Diez-Tejedor E, Rodriguez-Albarino A, Frank A, Barreiro-Tella P. Absence status following metrizamide myelography: management of nonresponders. Eur Neurol 1988;28:341-4.
9. Obeid T, Yaqub B, Panayiotopoulos C, Al-Jasser S, Shabaan A, El-Din Hawass N. Absence status epilepticus with computed tomographic brain changes following metrizamide myelography. Ann Neurol 1988;24:582-4.
10. Ahmed I, Pepple R, Jones RP. Absence status epilepticus resulting from amipaque (metrizamide) and omnipaque (iohexol) myelography. Clin Electroencephalogr 1988;19:37-42.
11. Dalen K, Kerr HH, Wang A, Olsen RE, Wesolowski DP, Farah J. Seizure activity after iohexol myelography. Spine 1991;16:384.
12. Altschuler EM, Segal R. Generalized seizures following myelography with iohexol (Omnipaque). J Spinal Disord 1990;3:59-61.
13. Hauge O, Falkenberg H. Neuropsychologic reactions and other side effects after metrizamide myelography. AJR Am J Roentgenol 1982; 139:357-60.
14. Standnes B, Oftebal S-I, Weber H. Effect of levomepromazine on EEG and on clinical side effects after lumbar myelography with metrizamide. Acta Radiol Diagn 1982;23:111-4.
15. Gonsette RE, Liesenborghs L. Iohexol: a new nonionic contrast medium for myelography and cisternography with markedly reduced neurotoxicity. Invest Radiol 1985;20(suppl 1):32-6.
16. Product information. Amipaque (metrizamide). New York, NY: Winthrop Laboratories 1978.
17. Ahlgren P. Early and late side effects of water-soluble contrast media for myelography and cisternography: a short review. Invest Radiol 1980; 15(suppl 6):264-6.